Therapeutic Asset Ratings

3,848 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Axicabtagene Ciloleucel Follicular Lymphoma	AIDS Malignancy Consortium	P3	B (62)
Lenzumestrocel Amyotrophic Lateral Sclerosis	Corestemchemon, Inc.	P3	B (62)
TIL Melanoma	City of Hope Medical Center	P3	B (62)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Carcinoma, Non-Small -Cell Lung	BOE Technology Group Co., Ltd.	P2	B (62)
Ari-0001 DLBCL - Diffuse Large B Cell Lymphoma	GUSTAVO SALGUERO	P2	B (62)
cd22 car-transduced t cells B-cell Acute Lymphoblastic Leukemia	National Cancer Institute (NCI)	P2	B (62)
STAPULDENCEL Epithelial Ovarian Carcinoma	Peking University Third Hospital	P2	B (62)
Tisagenlecleucel Lymphoma, B-Cell	Sun Yat-sen University	P2	B (62)
Treg Cells Myeloproliferative Disorders	Stanford University	P2	B (62)
Cilta-Cel Multiple Myeloma	Janssen Research & Development, LLC	P4	B (61)
Jcar017 (Lisocabtagene Maraleucel) Follicular Lymphoma	Fred Hutchinson Cancer Center	P3	B (61)
Jcar017 (Lisocabtagene Maraleucel) Leukemia, Lymphocytic, Chronic, B-Cell	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	P3	B (61)
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD Acute Lymphocytic Leukemia (ALL)	Leland Metheny	P2	B (61)
Axicabtagene Ciloleucel Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	City of Hope Medical Center	P2	B (61)
Chimeric Antigen Receptor Modified T Cells Infusion Lymphoma	Chinese PLA General Hospital	P2	B (61)
Cart-19 Cells B-cell Acute Lymphoblastic Leukemia	Beijing Yongtai Ruike Biotechnology Company Ltd	P2/3	B (61)
AUTOLOGOUS CD34+ CELLS ENCODING .BETA.A-T87Q-GLOBIN GENE Beta-Thalassemia	CorrectSequence Therapeutics Co., Ltd	P3	B (60)
Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA) introduced transiently as ribonucleoprotein (RNP) complex, targeting the erythroid lineage-specific enhancer region of BCL11A (B-cell lymphoma/leukemia 11A). The site-specific cleavage by Cas9 forms a double strand break (DSB), which is subsequently repaired by nonhomologous end-joining (NHEJ), leading to the transcriptional repression of BCL11A, a repressor of ?-globin gene transcription Hydroxyurea Intolerance	Vertex Pharmaceuticals Incorporated	P3	B (60)
Kite-753 Relapsed or Refractory Large B-cell Lymphoma	Kite, A Gilead Company	P3	B (60)
Rondecabtagene Autoleucel Diffuse Large B Cell Lymphoma Refractory	Lyell Immunopharma, Inc.	P3	B (60)
Allo-501A Relapsed/Refractory Large B Cell Lymphoma	Allogene Therapeutics	P2	B (60)
Ari-0001 Acute Lymphoblastic Leukemia ,Lymphomas	Sara V. Latorre	P2	B (60)
Ari-0001 Primary Mediastinal B-cell Lymphoma (PMBCL)	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	B (60)
cd19/cd22-bispecific car-t cells B-Cell Lymphoblastic Leukemia/Lymphoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P2	B (60)
cd19/cd22-bispecific car-t cells B-Cell Lymphoma Stage I	Beijing Tongren Hospital	P2	B (60)

Showing 76 to 100 of 3,848 assets

PreviousPage 4 of 154Next